2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Multiple Myeloma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Radiation Injuries
2
Prostatic Neoplasms
2
Preleukemia
2
Precancerous Conditions
2
Osteosarcoma
2
Neoplasms by Histologic Type
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Chronic Conditions
2
Melanoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia, Lymphoid
2
Leukemia, Biphenotypic, Acute
2
Interventions
Gemcitabine
13
pembrolizumab
9
Specimen Handling
9
enfortumab vedotin
8
Cisplatin
8
Magnetic Resonance Spectroscopy
7
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
eribulin
2
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Radiotherapy
2
Platinum
2
Nephroureterectomy
2
Ipilimumab
2
Doxorubicin
2
Docetaxel
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled